# S100A1

## Overview
S100A1 is a gene that encodes the S100 calcium-binding protein A1, a member of the S100 family of proteins characterized by their EF-hand motifs, which facilitate calcium binding. The S100A1 protein functions primarily as an intracellular calcium sensor, playing a pivotal role in modulating calcium dynamics within cells. It is particularly significant in cardiac and skeletal muscle tissues, where it influences processes such as excitation-contraction coupling and energy metabolism. S100A1 interacts with key proteins like the sarcoplasmic reticulum Ca2+ ATPase (SERCA2) and the ryanodine receptor (RyR2), thereby regulating calcium uptake and release essential for muscle contraction and cardiovascular function (Kraus2009S100A1; Most2004Cardiac). Additionally, S100A1 is involved in various protein-protein interactions that impact cellular signaling pathways, highlighting its importance in both physiological and pathological contexts (Sun2020Molecular).

## Structure
The S100A1 protein is a member of the S100 family of calcium-binding proteins, characterized by its EF-hand motifs. Each monomer of S100A1 contains two EF-hand calcium-binding domains: a pseudo EF-hand in the N-terminal region and a canonical EF-hand in the C-terminal region (Wright2009S100A1:). The primary structure of S100A1 includes a unique cysteine residue, Cys 85, which can undergo thionylation, enhancing calcium-binding affinity and linking calcium and redox signaling pathways (Nowakowski2013Impact).

The secondary structure of S100A1 is composed of α-helices, which form a noncovalent X-type four-helix bundle at the dimer interface (Wright2009S100A1:). Upon calcium binding, S100A1 undergoes a conformational change that exposes a hydrophobic cleft, crucial for interactions with target proteins (Nowakowski2013Impact). This structural change involves a reorientation of helix III, creating a hydrophobic cleft on the protein's surface (Nowakowski2013Impact).

In its quaternary structure, S100A1 functions as a homodimer, with dimerization stabilized by hydrophobic interactions between helices I and I' of each monomer (Rohde2010S100A1:). This dimerization occurs independently of calcium binding, allowing S100A1 to function as an intracellular calcium sensor (Rohde2010S100A1:).

## Function
The S100A1 gene encodes a protein that is a member of the S100 family, known for its calcium-binding properties. In healthy human cells, S100A1 functions as an intracellular calcium sensor, undergoing conformational changes upon calcium binding to interact with specific target proteins. This interaction is crucial for modulating various cellular processes, particularly in cardiac and vascular cells (Kraus2009S100A1).

In cardiomyocytes, S100A1 is primarily located at the sarcoplasmic reticulum, where it plays a significant role in calcium dynamics. It interacts with key proteins such as the Ca2+ ATPase (SERCA2) and the ryanodine receptor (RyR2), enhancing calcium uptake and release, which is vital for proper cardiac excitation-contraction coupling and contractile performance (Kraus2009S100A1; Most2004Cardiac). S100A1 also influences mitochondrial calcium uptake, supporting energy metabolism in cardiac muscle (Kraus2009S100A1).

In endothelial cells, S100A1 regulates calcium signaling and nitric oxide production, contributing to vascular tone and blood pressure regulation (Kraus2009S100A1). Its presence in skeletal muscle, although at lower levels, enhances sarcoplasmic reticulum calcium release, influencing muscle contraction (Kraus2009S100A1). Overall, S100A1 is essential for maintaining normal cardiovascular and muscular function through its role in calcium homeostasis and signal transduction.

## Clinical Significance
Alterations in the expression of the S100A1 gene are associated with several cardiovascular diseases, particularly heart failure. Reduced levels of S100A1 are observed in end-stage heart failure, suggesting its role as a potential biomarker and therapeutic target (Heizmann2019S100; Du2002Impaired). S100A1 deficiency leads to impaired cardiac contractility, especially in response to β-adrenergic stimulation, and is linked to prolonged ventricular repolarization and abnormal calcium handling in cardiac cells (Wright2009S100A1:; Heizmann2019S100). 

In heart failure, S100A1 interacts with the ryanodine receptor (RyR2) and the SERCA/phospholamban complex, playing a crucial role in calcium cycling and muscle contractility. Its downregulation contributes to sarcoplasmic reticulum calcium leak, a factor in heart failure progression (Most2004Cardiac; Imbalzano2016Pathophysiological). Gene therapy approaches to restore S100A1 levels have shown promise in improving cardiac function and calcium homeostasis in animal models, indicating potential therapeutic applications (Wright2009S100A1:; Most2004Cardiac).

S100A1 is also implicated in neurological disorders, where elevated levels are associated with Alzheimer's disease. Antagonists targeting S100A1 may offer therapeutic benefits by reducing cytotoxic effects and improving neuronal resistance to pathological conditions (Wright2009S100A1:).

## Interactions
S100A1 is a calcium-binding protein that participates in various protein-protein interactions, playing a significant role in muscle contraction and cardiac function. It interacts with the ryanodine receptor (RyR), influencing calcium release in muscle cells, and the sarcoplasmic reticulum Ca2+-ATPase (SERCA), affecting calcium uptake (Sun2020Molecular). S100A1 also binds to the PEVK domain of titin, a protein involved in muscle contraction regulation. This interaction is modulated by calcium ion concentrations and can disrupt the actin-titin interaction, which otherwise delays filament sliding (Sun2020Molecular).

The protein forms a complex with the Receptor for Advanced Glycation End Products (RAGE), specifically interacting with its V domain. This interaction can trigger signaling cascades that lead to cell growth and proliferation. S100B, another member of the S100 protein family, can antagonize this interaction by blocking S100A1's binding to the RAGE V domain (Khan2018S100B). The interaction between S100A1 and S100B has been characterized using NMR spectroscopy, revealing specific residues involved in the binding interface (Khan2018S100B). These interactions highlight S100A1's role in various physiological processes and its potential implications in disease contexts.


## References


[1. (Wright2009S100A1:) Nathan T. Wright, Brian R. Cannon, Danna B. Zimmer, and David J. Weber. S100a1: structure, function, and therapeutic potential. Current Chemical Biology, 3(2):138–145, May 2009. URL: http://dx.doi.org/10.2174/187231309788166460, doi:10.2174/187231309788166460. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/187231309788166460)

[2. (Khan2018S100B) Md. Imran Khan, Yu-Kai Su, Jinhao Zou, Lee-Wei Yang, Ruey-Hwang Chou, and Chin Yu. S100b as an antagonist to block the interaction between s100a1 and the rage v domain. PLOS ONE, 13(2):e0190545, February 2018. URL: http://dx.doi.org/10.1371/journal.pone.0190545, doi:10.1371/journal.pone.0190545. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0190545)

[3. (Kraus2009S100A1) Carolin Kraus, David Rohde, Christian Weidenhammer, Gang Qiu, Sven T. Pleger, Mirko Voelkers, Melanie Boerries, Andrew Remppis, Hugo A. Katus, and Patrick Most. S100a1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. Journal of Molecular and Cellular Cardiology, 47(4):445–455, October 2009. URL: http://dx.doi.org/10.1016/j.yjmcc.2009.06.003, doi:10.1016/j.yjmcc.2009.06.003. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.yjmcc.2009.06.003)

[4. (Nowakowski2013Impact) Michał Nowakowski, Katarzyna Ruszczyńska-Bartnik, Monika Budzińska, Łukasz Jaremko, Mariusz Jaremko, Konrad Zdanowski, Andrzej Bierzyński, and Andrzej Ejchart. Impact of calcium binding and thionylation of s100a1 protein on its nuclear magnetic resonance-derived structure and backbone dynamics. Biochemistry, 52(7):1149–1159, February 2013. URL: http://dx.doi.org/10.1021/bi3015407, doi:10.1021/bi3015407. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi3015407)

[5. (Most2004Cardiac) Patrick Most, Sven T. Pleger, Mirko Völkers, Beatrix Heidt, Melanie Boerries, Dieter Weichenhan, Eva Löffler, Paul M.L. Janssen, Andrea D. Eckhart, Jeffrey Martini, Matthew L. Williams, Hugo A. Katus, Andrew Remppis, and Walter J. Koch. Cardiac adenoviral s100a1 gene delivery rescues failing myocardium. Journal of Clinical Investigation, 114(11):1550–1563, December 2004. URL: http://dx.doi.org/10.1172/jci21454, doi:10.1172/jci21454. This article has 167 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci21454)

[6. (Imbalzano2016Pathophysiological) Egidio Imbalzano, Giuseppe Mandraffino, Marco Casciaro, Sebastiano Quartuccio, Antonino Saitta, and Sebastiano Gangemi. Pathophysiological mechanism and therapeutic role of s100 proteins in cardiac failure: a systematic review. Heart Failure Reviews, 21(5):463–473, January 2016. URL: http://dx.doi.org/10.1007/s10741-016-9529-8, doi:10.1007/s10741-016-9529-8. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10741-016-9529-8)

[7. (Heizmann2019S100) Claus W. Heizmann. S100 proteins: diagnostic and prognostic biomarkers in laboratory medicine. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1866(7):1197–1206, July 2019. URL: http://dx.doi.org/10.1016/j.bbamcr.2018.10.015, doi:10.1016/j.bbamcr.2018.10.015. This article has 37 citations.](https://doi.org/10.1016/j.bbamcr.2018.10.015)

[8. (Rohde2010S100A1:) David Rohde, Julia Ritterhoff, Mirko Voelkers, Hugo A. Katus, Thomas G. Parker, and Patrick Most. S100a1: a multifaceted therapeutic target in cardiovascular disease. Journal of Cardiovascular Translational Research, 3(5):525–537, July 2010. URL: http://dx.doi.org/10.1007/s12265-010-9211-9, doi:10.1007/s12265-010-9211-9. This article has 50 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12265-010-9211-9)

[9. (Du2002Impaired) Xiao-Jun Du, Timothy J. Cole, Nora Tenis, Xiao-Ming Gao, Frank Köntgen, Bruce E. Kemp, and Jörg Heierhorst. Impaired cardiac contractility response to hemodynamic stress in s100a1-deficient mice. Molecular and Cellular Biology, 22(8):2821–2829, April 2002. URL: http://dx.doi.org/10.1128/mcb.22.8.2821-2829.2002, doi:10.1128/mcb.22.8.2821-2829.2002. This article has 98 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.22.8.2821-2829.2002)

[10. (Sun2020Molecular) Bin Sun and Peter M. Kekenes-Huskey. Molecular basis of s100a1 activation and target regulation within physiological cytosolic ca2+ levels. Frontiers in Molecular Biosciences, June 2020. URL: http://dx.doi.org/10.3389/fmolb.2020.00077, doi:10.3389/fmolb.2020.00077. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2020.00077)